W H AT W E D O : M AT E R I A L S C I E N C E 5 CUSTOM FORMULATION We sell solutions not commodities. D is t. ) R P M P P G K W R F U L A V Y G C P IF F F M C H X L H U N E M N F O E E C L K R A S C L A S H C E G R A A L B Median: 5%Median: 3% Source: Peer data per Bloomberg market data as of February 5, 2021 Avient reflects 2021 estimated revenue of $4,100M and excludes one-time synergy capture CAPEX ($20M) Avient Specialty Formulators Other Chemical/Specialty Companies Free Cash Flow Conversion (1) 2021E (%) Being asset light helps us to generate strong free cash flow that is in line with specialty formulators. Free cash flow conversion calculated as (EBITDA – Capex) / EBITDA Median: 83% Median: 76% H I G H F R E E C A S H F L OW C O N V E R S I O N Avient reflects 2021 estimated EBITDA of $510M and excludes one-time synergy capture CAPEX ($20M) Source: Peer data per Bloomberg market data as of February 5, 2021 85 87 86 86 81 81 59 92 88 81 79 79 79 76 76 75 73 67 67 64 60 7 A vi e n t P P G K W R R P M F U L A V Y G C P IF F F M C U N V R H X L E M N B N R E C L C E A S H F O E G R A H U N K R A S C L A L B Source: Peer data per Bloomberg market data as of February 5, 2021 Total Enterprise Value / 2021E EBITDA Our current valuation implies an EBITDA multiple that is significantly below specialty formulator peers and our historic valuations, when the company had considerable exposure to more cyclical and challenging end markets.

S E M I C O N D U C TO R PAC K A G IN G O E M S P E C I A L T Y , S T A T I C D I S S I P A T I V E P A C K A G I N G • Provide protection against electrostatic discharge (ESD) and environmental variations • Ensure highly specialized, clean manufacturing conditions • Deliver stringent quality control of ionic and metal contamination • Maintain availability of raw materials across a global supply chain • Ability to translate production globally • Protected critical electronics from ESD while providing an environmental barrier • Adhered to strict quality and cleanliness controls from raw material handling through production to help maintain high-purity standards, such as ultra-clean feeders, deionized water, and specific HVAC systems, supporting quality initiatives, including PCS reviews, eCoA, and HA assessments • Exceeded customer expectations for controlling ionic and metal contamination down to parts per billion (PPB) • Offered global capabilities with local support and material supply to meet growing semiconductor industry needs Stat-Tech Static Dissipative Formulations KEY REQUIREMENTS WHY AVIENT?

a) (b) (c) (d) (e) (f) (g) (h) 7. a) (b) (c) (d) (e) (f) 8. a) (b) (c) (d) (e) (f) (g) 9.

D is t. ) K W R P P G F U L R P M A V Y F M C H U N H X L S C L E C L E M N C E A S H Source: Peer data per Bloomberg market data as of February 15, 2022. Free cash flow conversion calculated as (EBITDA – Capex) / EBITDA H I G H F R E E C A S H F L OW C O N V E R S I O N Avient reflects 2021 estimated EBITDA of $635M and estimated CAPEX of $90M (excludes IT system upgrade of $25M and synergy capture CAPEX of $20M) Source: Peer data per Bloomberg market data as of February 15, 2022 86 89 85 80 76 76 89 85 79 78 76 76 76 70 69 63 8 A vi e n t K W R P P G F U L A V Y R P M F M C U N V R H U N B N R H X L E C L C E A S H E M N S C L A L B Source: Peer data per Bloomberg market data as of February 15, 2022 Total Enterprise Value / 2022E EBITDAWith the Clariant Color business acquisition and divestment of the PP&S business, our exposure is now concentrated in less-cyclical and high-growth markets. O U R VA LUATI O N V E R S U S P E E R S Avient Specialty Formulators Other Chemical/Specialty Companies 5.4 8.5 10.1 10.0 15.7 15.0 14.2 12.7 10.2 25.0 19.7 17.7 13.2 12.3 10.0 9.9 8.9 8.5 8.3 6.6 A vi e n t (2 0 1 1 ) A vi e n t (2 0 1 6 ) A vi e n t (2 0 2 1 ) A vi e n t (T o d a y) R P M K W R P P G A V Y F U L A L B E C L H X L A S H F M C B N R E M N U N V R C E S C L H U N Historic Multiple S U M M A RY: W H Y I N V E S T I N AV I E N T ?

D is t. ) K W R R P M P P G A V Y F U L G C P IF F H X L F M C F O E H U N E C L K R A E M N A S H C E S C L G R A A L B Median: 5%Median: 3% Source: Peer data per Bloomberg market data as of April 27, 2021 Avient reflects 2021 estimated revenue of $4,300M and excludes one-time synergy capture CAPEX ($20M) Avient Specialty Formulators Other Chemical/Specialty Companies Free Cash Flow Conversion (1) 2021E (%) Being asset light helps us to generate strong free cash flow that is in line with specialty formulators. Free cash flow conversion calculated as (EBITDA – Capex) / EBITDA Median: 84% Median: 77% H I G H F R E E C A S H F L OW C O N V E R S I O N Avient reflects 2021 estimated EBITDA of $560M and excludes one-time synergy capture CAPEX ($20M) Source: Peer data per Bloomberg market data as of April 27, 2021 87 89 87 86 82 81 76 88 87 84 82 81 78 77 77 77 76 73 70 69 50 19 A vi e n t K W R P P G R P M A V Y F U L G C P F M C IF F H X L U N V R E C L A S H C E B N R F O E E M N G R A H U N K R A S C L A L B Source: Peer data per Bloomberg market data as of April 27, 2021 Total Enterprise Value / 2021E EBITDA Our current valuation with updated guidance implies an EBITDA multiple that is below specialty formulator peers and the majority of our chemical peers. With the Clariant Masterbatch acquisition and divestment of the PP&S business, our exposure is now concentrated in less-cyclical and high-growth markets, with increased geographic diversification and a more specialized portfolio that can significantly expand EBITDA margins. 20 Avient reflects 2021 estimated EBITDA of $560M O U R VA LUATI O N V E R S U S P E E R S Avient Specialty Formulators Other Chemical/Specialty Companies 10.2 17.7 16.0 14.9 14.6 11.6 11.1 26.7 24.0 22.8 14.3 12.7 11.5 11.2 11.1 11.0 10.3 10.1 9.5 9.4 8.3 7.0 A vi e n t K W R A V Y R P M P P G G C P F U L A L B H X L E C L IF F F M C B N R A S H G R A F O E S C L E M N U N V R C E K R A H U N Median: 11.1xMedian: 14.8x S U M M A RY: W H Y I N V E S T I N AV I E N T ?

Whether an additional line at an existing manufacturing plant, or a new facility in a growing region, we ramp-up quickly and cost-efficiently. 43 Capex / Revenue 2022E (%) AV I E N T I S A S S E T L I G H T Avient Specialty Formulators Other Chemical/Specialty Companies 2 3 2 2 2 3 4 3 3 5 5 7 7 8 11 A vi en t A vi en t P F F U L K W R P P G R P M A V Y F M C H U N H X L E C L E M N C E A S H S C L Source: Peer data per Bloomberg market data as of April 21, 2022. Free cash flow conversion calculated as (EBITDA – Capex) / EBITDA H I G H F R E E C A S H F LOW C O N V E R S I O N Avient reflects 2022 estimated EBITDA of $635M and estimated CAPEX of $90M (excludes IT system upgrade of $15M and synergy capture CAPEX of $10M) Avient PF reflects 2022 modelled EBITDA of $660M and estimated CAPEX of $120M to reflect Dyneema run-rate CAPEX, as well as potential sale of Distribution. Source: Peer data per Bloomberg market data as of April 21, 2022 86 82 86 86 84 78 77 89 86 81 80 76 76 76 67 67 11 (12) A vi en t A vi en t P F F U L K W R P P G R P M A V Y F M C U N V R B N R H U N H X L E C L C E A S H E M N S C L A LB 12% 18% 16% 15% 15% 14% 14% 28% 28% 26% 25% 22% 21% 19% 16% 12% 9% 9% A vi en t T od ay A vi en t P F A V Y P P G K W R FU L R P M C E A LB FM C A S H E C L E M N H X L H U N S C L B N R U N V R Median: 21%Median: 15% 2 0 2 2 E B I T DA M A RG I N S V S .

GUIDANCE ( T O TA L C O M PA N Y ) 6 $845 $846 Guidance Actual $125 $134 Guidance Actual Sales Adjusted EBITDA (in millions) $0.55 $0.63 Guidance Actual Adjusted EPS (in millions) Q1 2023 PERFORMANCE VS. Avient Specialty Formulators Other Specialty / Chemical Companies 2023E(%) 32 79 87 83 81 76 73 90 79 77 76 73 69 60 22 A vi e n t K W R P P G F U L A V Y R P M F M C C E H X L A S H E C L H U N E M N S C L M U LT I P L E E X PA N S I O N Avient Specialty Formulators Other Specialty / Chemical Companies Source: Peer data per Bloomberg as of April 28, 2023 Note: Avient reflects 2023 adjusted EBITDA guidance of $530M and closing share price of $38.51. Avient 2011 and 2018 valuations reflect trailing 12 months EBITDA at December 31 of the respective years. 33 EV / 2023E EBITDA Historic Multiple 6.5 8.3 9.9 14.6 13.7 13.0 11.9 8.8 18.7 17.4 11.8 10.0 9.7 9.1 8.0 7.9 A vi e n t (2 0 1 1 ) A vi e n t (2 0 1 8 ) A vi e n t (2 0 2 3 ) K W R P P G R P M A V Y F U L E C L H X L F M C A S H S C L C E E M N H U N Reconciliation of Non-GAAP Financial Measures (Unaudited) (Dollars in millions, except for per share data) Senior management uses comparisons of adjusted net income from continuing operations attributable to Avient shareholders and diluted adjusted earnings per share (EPS) from continuing operations attributable to Avient shareholders, excluding special items, to assess performance and facilitate comparability of results.

CABLE MANUFACTURER J A C K E T F O R P O W E R C A B L E • High tear resistance > 11 N/mm • High ESCR performance • Cost efficient solution • Hot pressure resistance above 80°C • Provided a jacket solution that complies with the LTS1 requirement as per BS 7655-6.1 • Enabled use in armored cables operating at a maximum conductor temperature of 90°C • Supported customer to optimize processing of the new material ECCOH™ LSFOH 5983 Formulation KEY REQUIREMENTS WHY AVIENT?

W H AT W E D O : M AT E R I A L S C I E N C E 4 CUSTOM FORMULATION We sell solutions not commodities. C O - C R E AT I O N D is t. ) K W R P P G A V Y F U L R P M G C P H X L F M C H U N IF F E C L A S H K R A E M N C E S C L A L B Median: 5%Median: 3% Source: Peer data per Bloomberg market data as of July 28, 2021 Avient reflects 2021 estimated revenue of $4,650M and excludes one-time synergy capture CAPEX ($20M) Avient Specialty Formulators Other Chemical/Specialty Companies Free Cash Flow Conversion (1) 2021E (%) Being asset light helps us to generate strong free cash flow that is in line with specialty formulators.

C O - C R E AT I O N D is t. ) K W R P P G A V Y F U L R P M G C P H X L F M C H U N IF F E C L A S H K R A E M N C E S C L A L B Median: 5%Median: 3% Source: Peer data per Bloomberg market data as of July 28, 2021 Avient reflects 2021 estimated revenue of $4,650M and excludes one-time synergy capture CAPEX ($20M) Avient Specialty Formulators Other Chemical/Specialty Companies Free Cash Flow Conversion (1) 2021E (%) Being asset light helps us to generate strong free cash flow that is in line with specialty formulators. Free cash flow conversion calculated as (EBITDA – Capex) / EBITDA Median: 81% Median: 78% H I G H F R E E C A S H F L OW C O N V E R S I O N Avient reflects 2021 estimated EBITDA of $580M and excludes one-time synergy capture CAPEX ($20M) Source: Peer data per Bloomberg market data as of July 28, 2021 87 90 86 82 80 78 73 87 82 82 79 79 78 78 77 76 71 67 46 A vi e n t K W R P P G A V Y F U L R P M G C P F M C U N V R C E IF F A S H E C L B N R E M N H X L H U N K R A S C L A L B (6) Source: Peer data per Bloomberg market data as of July 28, 2021 Total Enterprise Value / 2021E EBITDA Our current valuation with updated guidance implies an EBITDA multiple that is below specialty formulator peers and the median of other selected chemical / specialty companies.